05210nam 2200613 a 450 99620127080331620230607222359.01-282-12300-997866121230090-470-69892-60-470-69838-1(CKB)1000000000687605(EBL)470609(OCoLC)609849592(SSID)ssj0000354362(PQKBManifestationID)11277480(PQKBTitleCode)TC0000354362(PQKBWorkID)10313208(PQKB)10737552(MiAaPQ)EBC470609(Au-PeEL)EBL470609(CaPaEBR)ebr10297729(CaONFJC)MIL212300(EXLCZ)99100000000068760520000329d2002 uy 0engur|n|---|||||txtccrInsulin resistance[electronic resource] a clinical handbook /Andrew J. KrentzOxford ;Malden, Mass. Blackwell Sciencec20021 online resource (202 p.)Description based upon print version of record.0-632-05662-2 Includes bibliographical references and index.Insulin Resistance A Clinical Handbook; Contents; Preface; About the author; Acknowledgements; 1 Pathophysiology of insulin resistance; 1.1 Introduction; 1.2 Normal physiology; 1.2.1 Hormonal regulation of metabolism; 1.2.2 The insulin receptor; 1.2.3 Post-binding events; 1.2.4 Glucose metabolism; 1.2.5 Lipid metabolism; 1.2.6 Protein metabolism; 1.2.7 Ion transport; 1.3 The concept of insulin resistance; 1.3.1 Early studies of insulin action; 1.3.2 Radioimmunoassays for insulin; 1.4 Definitions of insulin resistance; 1.5 Assessment of insulin action in vivo1.5.1 Fasting insulin concentration1.5.2 Dynamic techniques-endogenous insulin; 1.5.3 Dynamic techniques-exogenous insulin; 1.5.4 Mathematical modelling techniques; 1.5.5 Insulin suppression test; 1.5.6 Hyperinsulinaemic euglycaemic clamp technique; 1.5.7 Complementary techniques; 1.6 Mechanisms of insulin resistance; 1.6.1 Genetic defects; 1.6.2 Acquired forms of insulin resistance; 1.6.3 Fetal origins hypothesis; 1.7 Further reading; 2 Insulin resistance in clinical medicine; 2.1 Clinical features; 2.2 Factors influencing insulin sensitivity; 2.2.1 Normal variation in insulin action2.2.2 Sex2.2.3 Age; 2.2.4 Physical exercise; 2.2.5 Tobacco; 2.2.6 Alcohol; 2.3 Physiological states of insulin resistance; 2.3.1 Puberty; 2.3.2 Pregnancy; 2.3.3 Menstrual cycle; 2.3.4 The menopause; 2.4 Severe insulin-resistance syndromes; 2.5 Insulin resistance and cardiovascular risk; 2.5.1 Syndrome X; 2.5.2 Obesity; 2.5.3 Regional adiposity; 2.5.4 Impaired glucose tolerance; 2.5.5 Type 2 diabetes mellitus; 2.5.6 Essential hypertension; 2.5.7 Dyslipidaemia; 2.5.8 Endothelial dysfunction; 2.5.9 Microalbuminuria; 2.5.10 Hyperuricaemia; 2.5.11 Impaired fibrinolysis2.5.12 Polycystic ovary syndrome2.5.13 Non-alcoholic steatohepatitis; 2.6 Other disorders associated with insulin resistance; 2.6.1 Counter-regulatory hormone secretion; 2.6.2 Endocrinopathies; 2.6.3 Chronic renal failure; 2.6.4 Hepatic cirrhosis; 2.6.5 Cardiac failure; 2.7 Miscellaneous inherited disorders; 2.8 Drug-induced insulin resistance; 2.9 Further reading; 3 Management of insulin resistance and associated conditions; 3.1 Non-pharmacological measures; 3.1.1 Medical nutrition therapy; 3.1.2 Physical activity; 3.1.3 Alcohol; 3.1.4 Tobacco; 3.2 Drugs for type 2 diabetes; 3.2.1 Biguanides3.2.2 Thiazolidinediones3.2.3 Sulphonylureas; 3.2.4 Meglitinide analogues; 3.2.5 α-Glucosidase inhibitors; 3.2.6 Insulin; 3.3 Antiobesity drugs; 3.3.1 Sibutramine; 3.3.2 Orlistat; 3.3.3 Leptin; 3.2.4 β3-adrenocepter agonists; 3.4 Lipid-modifying drugs; 3.4.1 Fibric acid derivatives; 3.4.2 Acipimox; 3.4.3 Statins; 3.4.4 Omega-3 fatty acids; 3.5 Antihypertensive drugs; 3.2.4 β-adrenocepter agonists; 3.5.2 Calcium-channel blockers; 3.5.3 Angiotensin converting enzyme inhibitors; 3.5.4 Angiotensin II receptor antagonists; 3.5.5 α1-Receptor blockers; 3.5.6 Selective imidazoline receptor agonists3.5.7 AspirinInsulin resistance, defined as a reduced biological action of insulin, has emerged as a major factor in the development and progression of a number of common non-communicable diseases in man. The role of insulin resistance in the aetiology of type 2 diabetes is particularly well-established. However, insulin resistance has also come to be regarded as a key component of a broader syndrome of common metabolic defects that conspire to increase the risk of atherosclerotic coronary heart disease. The ramifications of insulin resistance now embrace many different medical specialties. The objeInsulin resistanceHandbooks, manuals, etcInsulin resistance616.4/6207Krentz Andrew J937191MiAaPQMiAaPQMiAaPQBOOK996201270803316Insulin resistance2110860UNISA01722nam 2200517Ia 450 991069992050332120110428145619.0(CKB)5470000002406755(OCoLC)716226418(EXLCZ)99547000000240675520110428d2010 ua 0engurmn|||||||||txtrdacontentcrdamediacrrdacarrierFission Surface Power System initial concept definition[electronic resource]Cleveland, Ohio :National Aeronautics and Space Administration, Glenn Research Center,[2010]1 online resource (iv, 48 pages) illustrations, colorNASA/TM ;2010-216772Title from title screen (viewed on April 28, 2011)."August 2010."Includes bibliographical references (page 48).Nuclear reactorsnasatNuclear electric power generationnasatDesign analysisnasatCost effectivenessnasatRisknasatSystems integrationnasatFissionnasatNuclear reactors.Nuclear electric power generation.Design analysis.Cost effectiveness.Risk.Systems integration.Fission.Mason Lee1406252Poston David(David Irvin)1412476NASA Glenn Research Center.GPOGPOBOOK9910699920503321Fission Surface Power System initial concept definition3540221UNINA